Search company, investor...

Sarossa Capital

sarossaplc.com

Founded Year

2001

Stage

Series B | Alive

Total Raised

$1.4M

Last Raised

$1.1M | 20 yrs ago

Revenue

$0000 

About Sarossa Capital

Sarossa, formerly Antisoma, is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation.

Headquarters Location

17 The Esplanade St. Helier

Jersey, England, JE1 1WT,

United Kingdom

Missing: Sarossa Capital's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sarossa Capital's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Sarossa Capital News

Sarossa plc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 28112017 Prices from USD $250

Jan 1, 2018

Summary Sarossa plc Sarossa, formerly Sarossa Capital Limited, is an investment holding and management company. The company principally makes investment in and growth and development of businesses which present opportunities for value creation. It focuses on portfolio investment in major international markets through its partners and customers with an international profile. It has holdings in Silence Therapeutics Plc, a novel RNAi therapeutics development company; Plant Health Care Plc, a provider of novel patent protected biological products to the global agriculture markets; Avesoro Resources Inc, handles exploration and development of gold deposits; and Cambian Group Plc, offers specialist behavioral health services for children in the UK. Sarossa is headquartered in Channel Islands, the UK. Sarossa plc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Sarossa Capital Frequently Asked Questions (FAQ)

  • When was Sarossa Capital founded?

    Sarossa Capital was founded in 2001.

  • Where is Sarossa Capital's headquarters?

    Sarossa Capital's headquarters is located at 17 The Esplanade, Jersey.

  • What is Sarossa Capital's latest funding round?

    Sarossa Capital's latest funding round is Series B.

  • How much did Sarossa Capital raise?

    Sarossa Capital raised a total of $1.4M.

  • Who are the investors of Sarossa Capital?

    Investors of Sarossa Capital include Prosperitas Investment Partners, Anchorage Angels, Brown Foundation and Minerva Ventures.

  • Who are Sarossa Capital's competitors?

    Competitors of Sarossa Capital include Longevica, Molmed, Endocyte, PhaseBio Pharmaceuticals, CureTech and 11 more.

Compare Sarossa Capital to Competitors

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

A
Anaborex

Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.

G
Glycotope

Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.

N
Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

C
Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

T
Timi3 Systems

Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.